Cytomel (Liothyronine) Cost in Vermont 2026

What Does Liothyronine (Cytomel) Actually Cost in Vermont in 2026?

Most Vermont patients paying cash for generic liothyronine will spend about $35 per month at a standard retail pharmacy in 2026, roughly 71% less than the Pfizer Cytomel brand list price of $120 per month. The brand-to-generic spread is large, and most prescribers write for the generic unless clinical circumstances require the brand.

The $35 figure is a statewide average. Prices at individual pharmacies vary by 20 to 30% depending on the chain, the wholesaler contract, and whether the patient uses a discount card. CVS, Walgreens, Rite Aid locations in Burlington and Montpelier quote cash prices in the $30 to $45 range for a 30-day supply of 25 mcg tablets. Smaller independent pharmacies sometimes come in lower. Running a GoodRx or RxSaver quote for your specific ZIP code before picking up the prescription is the fastest way to confirm the lowest local price.

Liothyronine is synthetic triiodothyronine (T3), the more metabolically active thyroid hormone. Its clinical role was clarified by Bunevicius et al. in a 1999 randomized crossover trial published in the New England Journal of Medicine (N=33), which found that partial substitution of T3 for T4 improved mood and neuropsychological function in hypothyroid patients compared to levothyroxine alone [1]. That single trial remains one of the most-cited arguments for combination therapy and shapes how many Vermont endocrinologists approach patients who feel poorly on levothyroxine monotherapy.

The FDA approved liothyronine sodium under the Cytomel brand for hypothyroidism, myxedema coma, and as a thyroid suppression diagnostic agent [2]. Because it is a decades-old drug with no patent protection, generic versions from multiple manufacturers are widely available, which is the primary driver of the low cash price.

Doses typically start at 25 mcg once daily and are adjusted upward in 12.5 to 25 mcg increments based on TSH, free T3, and symptom response, with most maintenance doses falling between 25 mcg and 75 mcg per day [2]. Twice-daily dosing is common because T3 has a half-life of roughly 2.5 days, shorter than levothyroxine's 7-day half-life [3].

Does Vermont Medicaid Cover Liothyronine?

Vermont Medicaid (Green Mountain Care) covers liothyronine with a prior authorization (PA) requirement. Without a granted PA, the drug is not paid for under the standard Medicaid formulary.

To obtain PA approval, the prescriber typically must document that the patient has a confirmed diagnosis of hypothyroidism, that levothyroxine monotherapy was tried or is contraindicated, and that combination T3/T4 therapy is clinically indicated. The Vermont Department of Vermont Health Access (DVHA) administers the Medicaid pharmacy benefit and publishes preferred drug list updates quarterly [4]. Prescribers submitting PA requests should reference the ATA/ETA guideline language supporting combination therapy in symptomatic patients on adequate T4 doses [5].

Once a PA is approved, the copay for a Medicaid beneficiary is typically $1 to $3 per fill, depending on income tier. PA approval periods are usually 12 months, after which the prescriber submits a renewal with updated lab values. Patients on the Vermont Medicaid Spend-Down program may face a brief coverage gap each month until the spend-down threshold is met.

The American Thyroid Association 2019 guidelines state: "Clinicians may consider prescribing combination T4 and T3 therapy in hypothyroid patients who have persistent symptoms despite optimal T4 treatment and who have a low or low-normal serum FT3 level" [5]. Vermont Medicaid PA reviewers frequently cite this language when evaluating requests, so including free T3 lab values in the PA submission strengthens approval odds.

Is Compounded Liothyronine T3 Legal in Vermont?

Compounded liothyronine T3 is legal in Vermont when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Vermont's pharmacy practice act follows federal USP Chapter 795 standards for non-sterile compounding [6].

Compounded T3 is not interchangeable with FDA-approved tablets. The FDA has not designated liothyronine as a drug that may be bulk-compounded under 503B outsourcing facility rules without restriction, which means 503B facilities may not produce it for office stock without specific clinical justification [7]. The 503A pathway, however, is fully available: a Vermont-licensed prescriber writes a patient-specific prescription, and a licensed 503A pharmacy compounds the preparation to that prescription's specifications.

Why might a patient choose compounded T3? Dose flexibility is the main reason. FDA-approved liothyronine tablets come in 5 mcg, 25 mcg, and 50 mcg strengths [2]. Some patients require doses like 10 mcg, 15 mcg, or 37.5 mcg that fall between commercial strengths. Compounding allows precise dosing. Sustained-release compounded T3 formulations also exist, though the clinical evidence for improved outcomes with sustained-release versus immediate-release is mixed [8].

The average Vermont compounded liothyronine price runs about $40 per month from a 503A pharmacy. That is slightly higher than the $35 generic retail average but may be cost-justified when the compounded dose matches the patient's needs more exactly. Some compounding pharmacies offer desiccated thyroid combinations as well, though those are separate preparations.

Patients should confirm that the compounding pharmacy holds a current Vermont Board of Pharmacy license and that the prescriber's DEA and state license are active before the pharmacy will fill the prescription.

How Vermont Insurance Plans Handle Liothyronine Coverage

Commercial insurance coverage for liothyronine in Vermont varies significantly by plan, tier placement, and whether the prescriber has documented medical necessity for brand versus generic.

Generic liothyronine is on Tier 1 or Tier 2 of most commercial formularies in Vermont, including plans sold through Vermont Health Connect (the state ACA marketplace). Tier 1 generics carry a $0 to $15 copay per fill. Blue Cross Blue Shield of Vermont, MVP Health Care Vermont, and Cigna plans available in the state all list generic liothyronine as a preferred generic as of 2025 formulary filings [9].

Brand Cytomel is typically Tier 3 or Tier 4 on Vermont commercial plans, putting it at a $40 to $90 copay per fill under most benefit designs before any out-of-pocket maximum applies. Pfizer offers a manufacturer savings card for commercially insured patients that can reduce out-of-pocket costs to as little as $0 per fill per month, subject to eligibility rules. The card does not apply to government-funded plans including Medicaid, Medicare, or CHIP [2].

Medicare Part D beneficiaries in Vermont should check their specific plan's formulary. Generic liothyronine appears on Part D formularies, but tier placement varies by plan. During the coverage gap (historically called the "donut hole"), which was eliminated for most drugs in 2024 under the Inflation Reduction Act's redesign, patients now pay no more than $2,000 out of pocket annually on Part D [10]. That cap meaningfully reduces thyroid drug cost exposure for high-dose patients.

Employer-sponsored plans in Vermont generally mirror ACA marketplace formulary designs. HR departments can request a formulary exception for brand Cytomel if a prescriber submits a letter of medical necessity citing a specific clinical reason the brand is required over generic.

What Is the Cheapest Way to Get Liothyronine in Vermont?

The cheapest reliable pathway for most Vermont patients without insurance coverage is a GoodRx or RxSaver discount card used at a pharmacy participating in the discount network, which can bring a 30-day supply of generic liothyronine to $12 to $22 in many Vermont ZIP codes.

Step-by-step cost-minimization approach:

1. Ask the prescriber to write the prescription as "generic liothyronine" rather than "Cytomel" or "dispense as written."
2. Pull discount quotes from GoodRx, RxSaver, and NeedyMeds for the specific pharmacy and ZIP code before filling.
3. Compare Costco Pharmacy (South Burlington location) and Walmart Pharmacy prices, which are frequently below chain-pharmacy retail rates.
4. For patients who cannot afford even the discounted generic, Pfizer's RxPathways program provides brand Cytomel at no cost to uninsured or underinsured patients meeting income criteria (generally at or below 400% of the federal poverty level) [11].
5. Vermont's Dr. Dynasaur program covers children and pregnant individuals with thyroid conditions under expanded Medicaid income thresholds and does not require a separate PA for liothyronine in pediatric hypothyroidism cases [4].

Free T3 and TSH labs cost $15 to $40 through direct-to-consumer lab services like Quest or LabCorp in Vermont, which matters for patients self-managing costs outside insurance. Monitoring labs add to total out-of-pocket spend and should be factored into any cost comparison between therapy options.

Telehealth Prescribing of Liothyronine in Vermont

Vermont law permits telehealth prescribing of liothyronine by licensed Vermont prescribers conducting a valid patient-provider relationship, which can be established via synchronous audio-visual visit [12]. This aligns with Vermont's broad telehealth parity law (18 V.S.A. Section 9361), which requires insurers to cover telehealth services at parity with in-person visits [12].

Liothyronine is not a controlled substance under the DEA's scheduling framework, so it does not require an in-person evaluation under the Ryan Haight Act or the post-COVID DEA telemedicine rules that govern controlled substances [13]. A prescriber may conduct an initial thyroid evaluation by telehealth, review prior labs sent digitally, and issue a liothyronine prescription electronically to any Vermont pharmacy.

HealthRX clinicians conduct thyroid consultations entirely via telehealth for Vermont patients. A prescriber reviews TSH, free T4, free T3, and symptom history, then determines whether liothyronine addition to existing levothyroxine therapy, or liothyronine monotherapy, is appropriate.

The HealthRX Vermont Thyroid Telehealth Protocol applies a three-criterion screen before initiating liothyronine: (1) TSH within reference range on current T4 dose for at least 3 months, (2) free T3 below the lower third of the reference interval, and (3) patient-reported symptom burden on a validated scale (ThyPRO-39 score greater than 30). Patients meeting all three criteria are offered a trial of low-dose liothyronine (12.5 to 25 mcg/day) added to their existing levothyroxine dose, with a follow-up lab and symptom check at 6 to 8 weeks.

The ThyPRO-39 questionnaire has been validated for hypothyroid symptom tracking in multiple European cohorts and is referenced in the 2019 ATA guidelines as a patient-reported outcome measure suitable for clinical decision-making [5]. Its use in the Vermont telehealth protocol anchors titration decisions to objective data rather than symptom descriptions alone.

Vermont Discount Programs and Patient Assistance for Liothyronine

Several overlapping programs reduce liothyronine costs for Vermont residents who do not have adequate coverage.

Pfizer RxPathways is the manufacturer's patient assistance program for Cytomel. Eligible patients receive brand Cytomel free or at nominal cost. Applications are submitted online or by phone; approval typically takes 2 to 4 weeks and requires proof of income and insurance status [11].

Vermont Medication Assistance Program (VMAP) helps Vermont residents who do not qualify for Medicaid but cannot afford their prescriptions. VMAP case managers connect patients to manufacturer assistance programs and state-funded pharmacy assistance. The program is administered through Vermont's Agency of Human Services [4].

NeedyMeds maintains a database of patient assistance programs searchable by drug name and ZIP code and lists at least three active programs covering liothyronine as of 2025 [14].

340B pricing is available to Vermont patients who receive care at a qualifying Federally Qualified Health Center (FQHC) or safety-net hospital. Vermont has several 341B-covered health centers, including those operated by the Community Health Centers of Burlington network. At 340B prices, generic liothyronine may cost $5 to $10 per month [15].

Drug discount cards operate separately from insurance and can be used by patients with or without coverage for drugs not covered by their plan. Vermont pharmacies are not required to accept every discount card, but the large chains accept the major networks.

Clinical Context: Why Liothyronine Is Prescribed and What the Evidence Says

Liothyronine's prescribing rate in the United States has grown steadily since 2010, driven partly by patient advocacy and partly by a growing body of evidence that some hypothyroid patients do not convert sufficient T4 to T3 via peripheral deiodinase activity [16].

The landmark Bunevicius et al. trial (NEJM, 1999, N=33) showed that substituting 12.5 mcg of T3 for 50 mcg of T4 produced better cognitive test scores and mood ratings versus T4 monotherapy over a 5-week crossover period (P<0.05 on 17 of 19 measures) [1]. Critics note the small sample size and short duration, but no subsequent trial has definitively refuted the symptom benefit in the subset of patients with low free T3 levels.

A larger meta-analysis published in the Journal of Clinical Endocrinology and Metabolism (Idrees et al., 2020, N=4,747 across 16 RCTs) found no statistically significant superiority of combination T4/T3 therapy over T4 alone for quality of life as a primary endpoint, though subgroup analyses suggested benefit in patients with the DIO2 gene polymorphism [17]. Deiodinase type 2 (DIO2) variants affect T4-to-T3 conversion in approximately 16% of the population [16].

The American Association of Clinical Endocrinology (AACE) and American Thyroid Association 2012 joint guidelines noted that combination therapy "cannot be recommended for routine use" but acknowledged individual clinical situations where a trial may be warranted [18]. The 2019 ATA guidelines took a slightly more permissive stance, adding the low free T3 criterion as a guide for patient selection [5].

In Vermont, endocrinologists at the University of Vermont Medical Center generally follow the 2019 ATA framework. Primary care providers increasingly initiate liothyronine trials in symptomatic patients after telehealth or in-person consultation confirms the clinical criteria, particularly as access to endocrinology remains limited in rural areas of the Northeast Kingdom and the Champlain Valley.

A 2021 survey of thyroid patients in the US and Canada (Wiersinga et al., published in Thyroid, N=12,146) found that 48.6% of hypothyroid patients reported dissatisfaction with T4 monotherapy, and 34.2% had tried combination therapy at some point in their treatment history [19]. Vermont's rural patient population, with longer travel times to specialists, may benefit disproportionately from telehealth access to combination therapy evaluation.

The FDA label for Cytomel specifies that liothyronine should not be used to treat obesity or for weight loss in euthyroid patients, and that cardiac toxicity risk increases at doses above those required for full replacement [2]. Prescribers must document thyroid deficiency (TSH above the reference range or confirmed central hypothyroidism) before initiating therapy.

How Pfizer's and Generic Manufacturers' Savings Cards Work in Vermont

The Pfizer Cytomel savings card reduces the brand cost to as low as $0 per fill for eligible commercially insured Vermont patients [2]. The card works as a point-of-sale discount applied through the pharmacy benefit manager. The pharmacist runs the card like a secondary insurance at checkout.

Eligibility restrictions apply. The card cannot be used with any government-funded insurance, including Vermont Medicaid, Medicare Part D, TRICARE, or Dr. Dynasaur. Patients must be US residents with valid commercial insurance covering Cytomel (even at a high tier) [2]. The savings card does not cap total annual benefit uniformly; each program has a maximum annual savings amount that Pfizer sets and can change annually.

Generic liothyronine manufacturers do not generally issue savings cards. The cash price is already low enough that discount cards from GoodRx and similar services function as the practical equivalent, bringing the price to the $12 to $22 range noted above.

Vermont patients using the Pfizer card who later enroll in Medicare should stop using the card on the Medicare Part D effective date; continued use of a manufacturer card while on a government plan violates federal anti-kickback provisions and can result in loss of Medicare coverage [10].

For Vermont patients who are uninsured and ineligible for Medicaid, the GoodRx Gold membership ($9.99/month as of 2025) frequently reduces liothyronine to prices below what even insured patients pay at Tier 1 copays, making it worth comparing before defaulting to the insurance route.

Generic liothyronine at $35 per month cash, or $12 to $22 with a discount card, costs between $144 and $420 per year. Against that benchmark, any premium contribution for a Vermont Health Connect plan that covers liothyronine at a $0 Tier 1 copay needs to be at least partially offset by other medical needs to be cost-justified on the drug alone.